

United States Patent and Trademark Office



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023

WWW.USDIO GOV

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/016,686

11/02/2001

Alan Kingsman

674523-2012

20999 FROMMER LAWRENCE & HAUG 745 FIFTH AVENUE- 10TH FL. NEW YORK, NY 10151



CONFIRMATION NO. 4344
FORMALITIES LETTER
OC000000007739325

Date Mailed: 03/28/2002

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:


- A substitute specification in compliance with 37 CFR 1.52 because:
 - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT 674523-2012



THE STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Kingsman et al.

Serial No.

10/016,686

For

ANTIBODIES

Filed

November 2, 2001

Examiner

To Be Assigned

Art Unit

To Be Assigned

745 Fifth Avenue New York, NY 10151

EXPRESS MAIL

Mailing Label Number:

EV 073649542 US

Date of Deposit:

June 5, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

RESPONSE TO NOTICE

Commissioner for Patents Washington, D.C. 20231

Attention: Licensing and Review

Dear Sir:

This is in response to the notice mailed on April 25, 2002, requesting a reply within forty-five days. A copy of the notice is enclosed. The undersigned is a registered practitioner representing the Applicants in the above-named patent application.

On information and belief, Applicants Alan KINGSMAN, Susan Mary KINGSMAN, Christopher Robert BEBBINGTON, Miles William CARROL, Fiona Margaret ELLARD and Kevin Alan MYERS, all citizens of Great Britain, made and conceived this invention while employed by Oxford Biomedica, and all work related to the invention was performed by them or under their supervision.

Also on information and belief, the invention is related to the work the inventors are employed to perform and was made within the scope of their employment duties. Further, the

00070589

-1-

invention was made during working hours and with the use of facilities, equipment, materials, funds, information and services of Oxford Biomedica;

The invention relates to antibodies, alternatively in combination with radiation therapy utilized for the destruction of tumors. The invention is not useful in the production or utilization of special nuclear material or atomic energy;

To the best of my knowledge and belief, the invention was not made or conceived in the course of, or in connection with, or under the terms of any contract, subcontract or arrangement entered into with or for the benefit of the United States Atomic Energy Commission or its successors: Energy Research and Development Administration or the Department of Energy.

Respectfully submitted,

FROMMER LAWRENCE, & HAUG/LLP

By: Thomas J. Kowalski

Reg. No. 32,147 (212) 588-0800




UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT		ATTY. DOCKET NO.
10/016,686	11/	02/01	KINGSMAN, ET AL.	. (674523-2012

FROMMER LAWRENCE & HAUG 745 FIFTH AVENUE – 10TH FL. NEW YORK, NY 10151



APR 2 5 2002

LICENSING & REVIEW

IF NO RESPONSE TO THIS NOTICE IS RECEIVED WITHIN FORTY-FIVE DAYS, A FORMAL REQUIREMENT WILL BE ISSUED

The subject matter of this application appears to:

be "useful in the production or utilization of special nuclear material or atomic energy" as recited in 42 U.S.C. 2182 (Department of Energy (DOE)).

□"have significant utility in the conduct of aeronautical and space activities" as recited in 42 U.S.C. 2457 (National Aeronautics and Space Administration (NASA)).

Accordingly, no patent can issue on this application unless applicant(s) file a statement (under oath or in the form of a declaration as provided by 37 CFR 1.68) setting forth (1) the full facts concerning the circumstances under which the invention was made and conceived and (2) the relationship (if any) of the invention to the performance of any work under any contract or other arrangement with the Agency (ies) noted above. On the reverse side of this form is an example of an acceptable format for this statement. The language appearing in paragraphs III and/or IV of the example must appear if applicant is attempting to establish that no relationship (under item 2 above) exists.

If the invention disclosed in this application was developed under a contract, grant or cooperative agreement between the Agency indicated above and a person, small business or non-profit organization and rights to the invention have been determined by specific reference to 35 U.S.C. 202 in the contract, grant or cooperative agreement, then applicant need not submit the statement described above. Instead, applicant may file a verified statement (under oath or in the form of a declaration, 37 CFR 1.68) setting forth the information required by 35 U.S.C. 202(c)(6).

IF NO STATEMENT HAS BEEN RECEIVED WITHIN FORTY-FIVE DAYS OF THE MAIL DATE INDICATED ABOVE, a formal requirement for statement will then be issued. No provision is made for extension of the statutory thirty-day period for response to the formal requirement and the penalty for failure to file an acceptable and timely statement is abandonment of the application. Therefore, applicants are strongly encouraged to submit a statement at this time in order to avoid the issuance of a formal requirement.

IT IS IMPORTANT TO NOTE that the statement must accurately represent the property rights situation of the claimed invention if and when the application is found allowable. Thus, if during prosecution before the examiner, the claimed invention is so altered or the property rights situation so changed as to impact the accuracy of a statement submitted earlier, a supplemental statement must be filed. Failure to submit such additional information where appropriate may be considered a false representation of material facts and render the patent owner vulnerable to loss of patent rights and other sanctions as set forth in the statutes. The PTO will not review allowed applications for this possibility. The responsibility for complying with the statutes rests with the applicants.

Any questions regarding this requirement should be directed to Licensing and Review at (703) 306-4191.

m

I (We)	
citizens of	
residing at	
declare:	
That I (we) made and conceived the invention described a	and claimed in patent application:
Serial Numberfiled in the U	nited States of America on
titled	
(Check and complete either I or II below)	(Check III and/or IV below as appropriate)
☐ I. (For Inventors Employed by an Organization) That I (we) made and conceived this invention while employed	That to the best of my (our) knowledge and belief:
the invention is related to the work I am (we are) employed to perform and was made within the scope of my (our) employment duties; That the invention was made during working hours and with the use of facilities, equipment, materials, funds, information and services of Other relevant facts are (name of employer)	☐ III. The invention was not made or conceived in the course of, or in connection with, or under the terms of any contract, subcontract or arrangement entered into with or for the benefit of the United States Atomic Energy Commission or its successors: Energy Research and Development Administration or the Department of Energy.
	—AND/OR—
That to the best of my (our) knowledge and belief (and/or) based upon information provided byof: —OR—	☐ IV.The invention was not made (conceived or first actually reduced to practice) under nor is there any relationship of the invention to the performance of any work under any contract of the National Aeronautics and Space Administration.
☐ II. (For Self-Employed Inventors) That I (we) made	
and conceived this invention on my (our) own time using	
only my (our) own facilities, equipment, materials, funds, information and services. Other relevant facts are	
The undersigned inventor(s) declare further that all statements and that all statements made on information and belief are be with the knowledge that willful false statments and the like so Section 1001 of Title 18 of the United States Code and that he application or any patent issuing thereon.	elieved to be true and further that these statements are made made are punishable by fine or imprisonment, or both, under
nventor's Signature:	
Post Office Address:	
Date:	

Date: